Efficacy of DHMEQ, a NF-κB Inhibitor, in Islet Transplantation

Abstract

Inhibition of NF-κB activation by DHMEQ shortly after PITx suppresses HMGB1, which activates DCs and strengthens the magnitude of alloimmune responses; this permits long-term islet allograft acceptance, even in case of fewer islet allografts.